| Autor: |
Otten, Antonius T., Bourgonje, Arno R., Horinga, Petra P., van der Meulen, Hedwig H., van Leer-Buter, Coretta C., Dijkstra, Gerard, Visschedijk, Marijn C. |
| Přispěvatelé: |
Groningen Institute for Organ Transplantation (GIOT), Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI) |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Zdroj: |
Journal of Crohn's and Colitis, 16(Suppl(1)). Oxford University Press |
| ISSN: |
1873-9946 |
| Popis: |
Background Patients with Inflammatory Bowel Disease (IBD) frequently use immunomodulating treatment, which may render them at increased risk of attenuated immunogenicity after vaccination. Immunosuppressive drugs, such as TNF-α-antagonists, have shown an attenuating effect on serological response after SARS-CoV-2 infection. Here we assessed the effects of different types of immunosuppressive medications on the serological response after vaccination against SARS-CoV-2 in patients with IBD. Methods This was a prospective observational cohort study in patients with IBD of whom IgG antibody titers were measured after 2–10 weeks after full vaccination against SARS-CoV-2. Patient demographics, clinical characteristics as well as a previous history of SARS-Cov-2 infection, type of vaccine (mRNA or vector), and medication use were recorded at time of sampling. The primary study outcome was the anti-SARS-CoV-2 spike (S) antibody concentrations, measured using chemiluminescence microparticle immunoassay (CMIA) after full vaccination. Results 312 IBD patients were included (172 Crohn’s disease [CD] and 140 ulcerative colitis [UC]). Seroconversion (defined as titer of >50 AU/ml) was achieved in 98,3% of patients. Antibody concentrations were significantly lower in patients treated with TNF-α-antagonists vs. non-users of TNF-α-antagonists (geometric mean [95% confidence interval]: 2204 [1655–2935] vs. 5002 [4089–6116] AU/ml, P50 years) (-54%, P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
